On April 13, 2021, Hemanext announced that it had received CE Mark certification for Hemanext ONE® system, clearing the way for the medical device to be sold in European markets. On December 30, 2021, Hemanext submitted the Hemanext ONE® system for marketing authorization review by the U.S. Food and Drug Administration (FDA).
Recent Posts
- Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
- Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023